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BCR-associated factors driving 
chronic lymphocytic leukemia cells 
proliferation ex vivo
Cédric Schleiss1,2, Wassila Ilias1,2, Ouria Tahar1,2,3, Yonca Güler4, Laurent Miguet4,5, 
Caroline Mayeur-Rousse4,5, Laurent Mauvieux  4,5, Luc-Matthieu Fornecker4,6, 
Elise Toussaint4,6, Raoul Herbrecht4,6, Frédéric Bertrand2,7, Myriam Maumy-Bertrand2,7, 
Thierry Martin2,8, Sylvie Fournel9, Philippe Georgel  1,2, Seiamak Bahram  1,2,3 & 
Laurent Vallat  1,2,3,10
A chronic antigenic stimulation is believed to sustain the leukemogenic development of chronic 
lymphocytic leukemia (CLL) and most of lymphoproliferative malignancies developed from mature 
B cells. Reproducing a proliferative stimulation ex vivo is critical to decipher the mechanisms of 
leukemogenesis in these malignancies. However, functional studies of CLL cells remains limited 
since current ex vivo B cell receptor (BCR) stimulation protocols are not sufficient to induce the 
proliferation of these cells, pointing out the need of mandatory BCR co-factors in this process. Here, 
we investigated benefits of several BCR co-stimulatory molecules (IL-2, IL-4, IL-15, IL-21 and CD40 
ligand) in multiple culture conditions. Our results demonstrated that BCR engagement (anti-IgM 
ligation) concomitant to CD40 ligand, IL-4 and IL-21 stimulation allowed CLL cells proliferation ex vivo. 
In addition, we established a proliferative advantage for ZAP70 positive CLL cells, associated to an 
increased phosphorylation of ZAP70/SYK and STAT6. Moreover, the use of a tri-dimensional matrix of 
methylcellulose and the addition of TLR9 agonists further increased this proliferative response. This ex 
vivo model of BCR stimulation with T-derived cytokines is a relevant and efficient model for functional 
studies of CLL as well as lymphoproliferative malignancies.
Like in most mature lymphoproliferative malignancies, an antigenic stimulation is believed to drive the leukemo-
genic process in chronic lymphocytic leukemia (CLL)1–3. A restricted use of IGHV genes and the existence of ste-
reotypic B cell receptor (BCR) on CLL cells4–6 provides evidence in favor of antigenic stimulation where different 
microbial antigens, as well as auto-antigens, have been suspected as actors of this chronic stimulation7. In addi-
tion, a chronic BCR self-activation has been shown in subtypes of CLL cells8. Moreover, several signaling aberra-
tions have been described downstream of the BCR, notably in aggressive CLL with unmutated IGHV (UM-CLL), 
in which the expression of ZAP70 reinforces BCR responsiveness9–12. BCR activation, which is essential for the 
physiological development of lymphocytes13 would also be indispensable for the survival and proliferation of CLL 
cells in vivo2. Accordingly, withdrawal of this stimulation is believed to be responsible for the rapid spontaneous 
apoptosis of CLL cells ex vivo14. The cellular consequences of this BCR activation has been extensively studied and 
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we previously described the specific transcriptional15,16 and proteomic programs17 which are induced in aggres-
sive CLL cells following BCR ligation.
Nevertheless, a sustained soluble stimulation of the BCR induces apoptosis in CLL cells9,15,18–21 and 
BCR-associated factors are mandatory in inducing CLL cells proliferation. Several factors, are known for their 
role in CLL cells survival or proliferation, among which IL-2, IL-4, IL-10, IL-15, IL-21 and CD40L are promi-
nent22–25, but an exhaustive evaluation of their role as BCR-cofactors for CLL cells proliferation is still lacking. 
Difficulties to achieve robust CLL cell proliferation ex vivo led to the use of stromal cells26,27, activated T cells22,28–31  
or fibroblast (eventually CD40L transfected)21,22,30,32–34 as feeder cells. However, feeder cells’ interactions35 and 
secretion of IL-6, IL-10 or TGF-β can also participate in CLL cells survival and proliferation26, which makes the 
identification of essential leukemogenic factors difficult and prevents the specific evaluation of BCR ligation in 
the proliferative response in these models.
In this study, we aim to set-up culture conditions, primarily based on BCR ligation for patho-physiological 
relevance, inducing CLL cells proliferation. This study was conducted in two steps. We first aimed at establishing 
the optimal ex vivo model for CLL cells proliferation measured by carboxyfluorescein succinimidyl ester (CFSE) 
incorporation. For this, a selection of healthy and primary CLL cells were stimulated by anti-IgM ligation with or 
without co-stimulatory molecules (IL-2, IL-4, IL-10, IL-21, IL-15, sCD40L), at various concentration in different 
culture conditions. Next, using the optimized culture conditions, we analyzed the proliferative response of fresh 
negatively selected B cells isolated from a cohort of well characterized CLL patients, under informed consent, 
including clinical data, cell morphology, flow cytometry - including ZAP70 expression status-, FISH and IGHV 
mutational status, as these factors may impact the cell response to stimulation22,28,30,31. These culture conditions 
induced a proliferative response of a fraction of CLL cells, essentially ZAP70+, in soluble medium and a prolifer-
ation of nearly all CLL cells in 3D semi-solid medium, representing a valuable system for CLL functional studies.
Results
Establishing culture conditions for CLL cells proliferation ex vivo. To establish culture conditions 
for CLL cells proliferation after ex vivo activation, we first evaluated CFSE labeling in a small series of patient sam-
ples (n = 8). This approach allows calculating the percentage of dividing cells and the number of cell generations 
(Fig. S1). We first confirmed data from previous studies showing that ex vivo BCR activation by means of anti-
IgM ligation does not induce CLL cells proliferation when these cells are cultured in soluble medium (Figs 1A and 
S2A). Similarly, stimulation with IL-4, IL-21 or CD40L, used separately, in soluble medium, did not induce CLL 
cells proliferation either (Fig. 1A). We also confirmed that different combinations of cytokines, [CD40L + IL-4], 
[CD40L + IL-21] and [CD40L + IL-4 + IL-21] induced a weak (less than 40%) proliferation of CLL cells (Fig. 1A). 
Of note, IL-21, which has a pro-apoptotic effects on CLL cells34 potentiates the proliferating effect of IL-4 when 
sequentially added after IL-423 and therefore IL-21 was added 24 h after all initial IL-4 stimulation. However, 
when we analyzed the proliferative effect of a combination of cytokines added after initial BCR stimulation (IgM 
ligation), we established that, even if BCR activation associated to [CD40L + IL-4] or [CD40L + IL-21] allowed 
a weak proliferation, the combination of anti-IgM with [CD40L + IL-4 + IL-21] induces a higher proliferation 
Figure 1. Determination of the optimal culture conditions for CLL and healthy B cells proliferation ex vivo. (A) 
Effect of BCR and cytokines stimulation, isolated or in combination, on the proliferation of B cells harvested 
from CLL patients and cultured on soluble medium (n = 8; CLL samples #6, 14, 24, 42, 49, 52, 58 and 62) and 
(B) total B cells from healthy donors (n = 4) cultured in soluble medium. After initial CFSE staining at day 0, the 
percentage of dividing cells (CFSEdim) were evaluated by flow cytometry at day 6 for CLL cells samples and at 
day 4 for healthy B cells. Symbols represent CLL cells sub-types (circle: UM ZAP + ; triangle: M ZAP + ; square: 
M ZAP-). 95% confidence interval for median is shown in each group. *p < 0.05; **p < 0.01; ***p < 0.001.
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rate of CLL cells in soluble medium (Fig. 1A). Similar experiments confirmed the proliferative potential of these 
conditions on total B cells from healthy donors (Figs 1B and S2B). We analyzed the morphology of CLL cells 
submitted to these culture conditions. We observed the formation of clusters of proliferating cells in the culture 
medium (Fig. S1) and cytological analysis of these cells after cytocentrifugation at day 6 revealed in all cases a 
monomorphic evolution consisting in large cells with a high amount of basophilic cytoplasm, prominent nucleoli 
and a fine chromatin that were distinct from those of control unstimulated cells (Fig. S3A). Immunophenotyic 
analysis of proliferating CLL cells at day 6 after ex vivo stimulation showed a lower expression of CD5, an upreg-
ulation of CD138 but not of CD38 and no IgG expression on cell surface, as compared to the expression at day 
0 before stimulation (Fig. S3B) which underlined the biological relevance of this model of ex vivo stimulation.
Response of a cohort of CLL cells submitted to the selected culture conditions. Because of the 
clinical and biological heterogeneity of CLL patients, we analyzed the impact of these selected culture condi-
tions on the proliferative response of fresh CLL cells harvested from sixty-five untreated patients referred in 
Strasbourg Hospitals, essentially Binet stage A (58/65) (Table 1). Among them, 25 harbored unmutated IGHV 
genes (UM-CLL) and expressed the ZAP70 protein (ZAP70+), 29 had mutated IGHV genes (M-CLL) and did 
not express the ZAP70 protein (ZAP70−), 10 were ZAP70 + M-CLL and one was ZAP70− UM-CLL. We also 
analyzed the proliferation of total B cells (20 healthy blood-donors) and naïve (CD19+, CD27−, IgM+) B cells (16 
healthy blood-donors). All of the total B-cells (20/20) and 12 out of 16 naïve B cells exhibited more than 25% of 
dividing cells at day 4 (Fig. 2A) (median 62%; confidence interval (CI) of median [56;82] with up to 4 cell genera-
tions for total B cells and median 60%; CI [24;71] for naïve B cells with up to 5 cell generations). In the same con-
ditions, 24/59 (41%) of CLL cells samples proliferated (median 25%; CI [17;27]), showing up to four generations 
of proliferating cells at day 6 (Fig. 2A,B).
3D semi-solid matrix increases CLL cells proliferation ex vivo. Then we analyzed the impact of a 
tri-dimensional environment using a semi-solid medium (methylcellulose) where the selected culture conditions 
also showed their proliferative action (Fig. S4). This culture condition enhanced the proliferation rates and num-
ber of cell generations of nearly all CLL cells (89%; 34/38 samples) (Fig. 3A), with up to six generations observed 
at day 6 (Fig. 3B,C). Of importance, CLL cells stimulation on feeding cells (CD40L-transfected 3T6 cells) neither 
drove a higher proliferation rate (compared to the soluble stimulation alone) nor increased the number of gener-
ations of proliferating cells (Fig. S5A,B).
TLR9 agonists further increases CLL cells proliferation. Next, we tested the effects of CpG-ODN2006 
(known to affect B cells proliferation by TLR9 activation)31 in our culture conditions. While CpG-ODN2006 
alone did not induce CLL cells proliferation (for 35 out of 39 CLL cells tested), we observed increased responses 
(p < 0.0001) when cells were stimulated with CpG-ODN2006 combined to BCR and cytokines in soluble and 3D 
semi-solid medium (Fig. 4A–F). In addition, CpG/DSP30 and IL-2 cocktails being routinely used as metaphases 
inductors for cytogenetic diagnosis, we then compared our stimulation conditions with CpG-ODN2006 + IL-2 
or commercial premix DSP30/IL-2. The combination of CpG/DSP30 and IL-2 did not increase the prolifera-
tion rate, compared to BCR with our selected cytokine stimulation conditions, in soluble or semi-solid medium 
(Fig. S6A,B). Our work also confirmed previous reports36 showing that the combination of CpG-ODN2006 and 
IL-15 is a modest inducer of CLL cells proliferation. Nevertheless, IL-15 addition did not increase the prolifera-
tion rate, compared to our soluble BCR stimulation (Fig. S7A,B).
Proliferative advantage of ZAP70+ CLL cells in soluble medium. Analyzing the rate of CLL cells 
proliferation after BCR and cytokine stimulation according to their biological characteristics, we observed that 
proliferating cells, in soluble medium, exhibit the highest ZAP70 expression levels, compared to non-proliferating 
cells (p = 0.0043) (Fig. 5). Accordingly, 15/30 (50%) ZAP70+ CLL cells responded to the stimulation with up to 
four generations (median: 2 generations, with a significant (p = 0.0198) Pearson’s correlation coefficient between 
ZAP70 expression level and the number of cell generations), whereas only 8/28 ZAP70− CLL cells proliferate 
with a maximum of two generations. Of note, the percentage of IGHV gene identity and CD38 expression did not 
associate with the cell proliferation in this soluble model (not shown). In semi-solid medium, ZAP70+ CLL cells 
with mutated IGHV exhibit a proliferative advantage (Fig. 5).
When BCR ligation and cytokines are associated with CpG-ODN2006 stimulation, all CLL-cells respond 
equally in soluble or semi-solid medium, irrespective of the level of ZAP70 and the IGHV status (Fig. 5).
Increased ZAP70/SYK and STAT6 phosphorylation in proliferating ZAP70+ CLL cells. Given the 
heterogeneity of the proliferative response of ZAP70+ CLL-cells, we searched for signaling differences between 
responders (proliferating) and non-responders ZAP70+ cells. We performed western blots to analyze the main 
signaling pathways activated downstream of the BCR (e.g. ZAP70, pZAP/pSYK, pERK, pIkB) and the JAK/STAT 
pathway (e.g. pAKT and pSTAT6) in selected responders and non-responders amongst the ZAP70+ UM-CLL 
cells. Our results (Figs 6A and S8A,B) confirmed ZAP70 expression in all these CLL cells. They also suggested 
increased ZAP70Tyr319/SYKTyr352 phosphorylation before stimulation (at the steady state) and a further increase 
upon stimulation in responding ZAP70+ CLL cells, compared to non-responding cells (p = 0.03). IkB phospho-
rylation was evidenced upon stimulation in both non-responding (p = 0.03) and responding (p = 0.05) CLL cells. 
The main signaling pathway downstream IL-21R (pSTAT3), revealed no difference between responders (prolifer-
ating) and non-responders ZAP70+ cells (Fig. S9A–C). However, we observed an increased STAT6 phosphoryl-
ation in responding CLL cells, compared to non-responders (p = 0.03). STAT6 being a major component of the 
IL-4 receptor signaling pathway, this result was corroborated by the significantly reduced CLL cells proliferation 
found in the absence of IL-4 in the stimulatory cocktails, or when a selective JAK3 inhibitor (PF-956980) was 
used (Fig. 6B).
www.nature.com/scientificreports/
4ScIentIfIc REpoRTS |           (2019) 9:701  | DOI:10.1038/s41598-018-36853-8
Discussion
Engagement of the BCR is a crucial event in CLL leukemogenesis, but is not sufficient to induce cell prolifer-
ation ex vivo, and is even known to promote B cells apoptosis15,18. This caveat can be prevented with coated 
anti-IgM stimulation, which promotes CLL cells survival9 but does not induce cell proliferation either. Therefore, 
BCR-induced CLL-cell proliferation in vivo likely requires additional co-stimulatory signals and proliferative 
properties of several soluble factors have been described in the literature. Here we performed an exhaustive study 
of the role of several co-stimulating factors, used solely or in combination, on top of anti-IgM stimulation, to 
identify mandatory factors sustaining CLL cells proliferation ex vivo. We evaluated CD40L (CD154), a TNF fam-
ily member expressed on activated T-cells that activates the TNFRSF5 receptor on B cells and triggers several 
signaling pathways, including NF-kB and ERK, and participates in the survival, proliferation and differentiation 
of B cells37. IL-4, which is mainly secreted by T Follicular helper cell (TFH), activates STAT6 and participates in 
the activation and survival of B cells38,39, was also tested. Finally, we considered IL-21, which is produced by TFH, 
NKT and TH17 cells, for its role in the induction of JAK/STAT signaling in B cells40. IL-21 is known to induce 
apoptosis34, but plays also a role in CLL cells proliferation after priming by IL-4 and CD40L22,23, IL-21 was added 
at Day 1 in the culture medium. We also tested, isolated or in combination, IL-10, IL-2, IL-15, which did not show 
gain in BCR-induced proliferation effect (not shown) and were not considered further.
Several groups have already used soluble CD40L, Il-2, IL-4, IL-10, IL15 or IL-21, isolated or in combination, 
to stimulate CLL cells22–24,30,34,39. However, to our knowledge, this is the first study to evaluate their role as BCR 
co-stimulating factors in soluble conditions without the support of feeder cells. Indeed, most ex vivo models of 
CLL cells proliferation described in the literature are not consistently defined, as they used co-cultures of fibro-
blasts expressing CD40L, sometimes in the presence of IL-2122, to favor CLL cells survival32,33. Co-cultures involv-
ing autologous activated T-cells have also been reported22,28, including in association with a fibroblast layer30. The 
nature of the cytokines used suggests a T cell dependent activation, possibly delivered by follicular helper T-cells 
found in the proliferative centers described in secondary lymphoid organs of CLL patients41–43.
Our systematic analysis of BCR ligation associated to different co-stimulations enabled us to select the optimal 
condition combining BCR activation and co-stimulating factors [CD40L + IL-4 + IL-21] driving CLL cells prolif-
eration. This cocktail was used to stimulate CLL cells harvested from a cohort of patients with different biological 
characteristics (IGHV UM/M, ZAP70+/− and CD38+/−) and control B cells from healthy donors. In these 
conditions, about 1/3 of CLL cells proliferate at day 6 after stimulation, among which ZAP70+ B cells appeared 
particularly responsive. The same stimulation, performed on a 3D semi-solid (methylcellulose) medium, induced 
the proliferation of nearly all (89%) CLL cells, with a high number of cell generation, representing an efficient 
model of CLL cells proliferation.
A T-dependent help for CLL cells proliferation has not yet been proven in vivo. In our model, T-cells-derived 
cytokines (CD40L, IL-4 and IL-21) enable BCR-activated CLL proliferation which reinforces this hypothesis. 
Furthermore, it was shown in the literature that the proliferation of CLL cells xenografted in NOD-SCID mice 
required concomitant TFH graft in vivo44, which also sustains this model. Of note, our results showed the impor-
tance of IL-4 and IL-21 co-stimulation (in addition to anti-IgM and CD40L) for CLL cells proliferation, whereas 
the sole association of anti-IgM and CD40L was sufficient to induce healthy B cells proliferation. Finally, BCR and 
cytokine stimulation on a tri-dimensional matrix of methylcellulose allowed the proliferation of most of the CLL 
cells tested, irrespectively of their biological characteristics. This result, which may reflect the natural history of 
leukemogenesis of CLL cells within secondary lymphoid organs may further enhance the pathophysiological rele-
vance of our ex vivo model. Furthermore, the individualization of clusters of proliferating cells, distributed in this 
3D matrix, could allow studying the heterogeneity of intraclonal responsiveness to various drugs in future studies.
High proliferation rate (up to 80% with 6–8 cell generations) was only observed in a subset of CLL cells. Such 
variability may reflect the clinical and biological heterogeneity of CLL patients, among whom those characterized 
by ZAP70+ CLL cells appeared particularly responsive, as also observed by others32,45. However, we noted that 
all ZAP70+ CLL cells do not equally respond to ex vivo stimulation, which prompted us to investigate in more 
details the molecular features of the responders and non-responders among this subpopulation. We first con-
firmed by Western blots the presence of ZAP70 protein in these cells. In CLL cells, ZAP70 activates and extends 
SYKTyr352 phosphorylation, independently of ZAP70 phosphorylation10,46. This activation induces another 
SYKTyr526 phosphorylation, leading to downstream BCR signaling. Our results, performed on a limited number 
of CLL cell samples (4R vs 3 NR) show that CLL cells that proliferate in soluble medium could achieved a higher 
initial ZAP70Tyr319/SYKTyr352 phosphorylation, the mechanism of which remains to be investigated. We also show 
a concomitant increase in pSTAT6 in the proliferating ZAP70+ CLL cells, suggesting that signaling downstream 
of the IL-4R could participate in CLL proliferation, which reinforces the need to evaluate therapeutic agents 
inhibiting this pathway39,47. More generally, these results highlight the need to explore the functionality of mul-
tiple signaling pathways in relation to the heterogeneity of CLL patients. Indeed, as more kinases inhibitors are 
now available for therapeutic use, there appears to be a rational for further personalized use of these molecules.
In conclusion, this study demonstrates the relevance of the BCR activation, combined with a defined set of 
cytokines, to recapitulate CLL cells proliferation ex vivo. In addition, it highlights the potential roles of T cells in 
this process. The soluble and 3D culture models established here represent valuable systems for further studies 
aimed at characterizing the initial steps of malignant evolution of the CLL, with the ultimate goal to identify novel 
targets for therapeutic purpose.
Materials and Methods
Subjects and B cell isolation. Peripheral lymphocytes were isolated from 65 untreated CLL patients 
and from 36 healthy blood donors (buffy coats obtained from the Etablissement Français du Sang Grand Est, 
Strasbourg, France). All subjects gave written informed consent for this study, which was approved by the insti-
tutional review board of the Strasbourg University Hospitals and all experiments were performed in accordance 
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Sample Sex
Age at 
diagnosis
IGHV 
status*
VH identity 
(%)
ZAP70 
status**
CD38 
*** cytogenetic
Binet 
stage
Lymphocytes 
(G/L)
CLL-01 M 67 M 96 neg neg 0 A 3
CLL-03 M 82 M 87 neg neg del13q, del17p B 12
CLL-04 M 43 M 94 neg neg del13q A 89
CLL-05 M 51 M 90 neg neg 0 A 62
CLL-07 M 63 M 90 neg neg del13q C 60
CLL-08 M 58 M 93 neg neg 0 A 18
CLL-09 M 60 M 93 neg neg nd A 9
CLL-12 F 64 M 93 neg neg 0 A 47
CLL-15 M 57 M 91 neg pos 0 A 43
CLL-17 M 59 M 95 neg neg nd A 27
CLL-18 F 53 M 94 neg nd nd A 55
CLL-27 M 77 M 92 neg neg del13q A 12
CLL-30 M 46 M 92 neg neg del13q C 124
CLL-31 F 68 M 93 neg neg del13q A 13
CLL-34 M 73 M 91 neg neg 0 A 35
CLL-35 F 49 M 93 neg neg del13q A 10
CLL-37 M 54 M 92 neg neg nd A 15
CLL-38 F 57 M 93 neg neg del13q A 7
CLL-39 F 55 M 96 neg neg 0 A 16
CLL-43 M 45 M 95 neg nd del13q A 29
CLL-45 M 63 M 92 neg neg nd A 12
CLL-49 M 44 M 95 neg neg nd A 65
CLL-50 F 48 M 93 neg neg 0 A 94
CLL-52 M 76 M nd neg neg 0 A 44
CLL-60 F 78 M 93 neg neg nd A 4
CLL-61 M 61 M 97 neg neg nd A 12
CLL-62 F 61 M 98 neg neg del13q A 8
CLL-63 M 44 M 93 neg neg del13q A 13
CLL-64 M 70 M 91 neg nd nd A 8
CLL-06 M 73 M 97 pos neg del13q A 34
CLL-11 F 41 M 92 pos neg 0 A 13
CLL-16 M 60 M 94 pos neg nd A 24
CLL-20 M 57 M 93 pos nd 0 A 10
CLL-21 M 59 M 96 pos neg del13q A 6
CLL-28 M 73 M 94 pos neg del13q A 11
CLL-29 F 56 M 96 pos neg trisom12, del11q A 35
CLL-46 F 42 M 96 pos nd del13q B 32
CLL-47 F 33 M 96 pos neg del13q A 6
CLL-56 M 63 M 97 pos pos nd A 9
CLL-59 F 75 UM 99 neg pos nd A 8
CLL-02 M 77 UM 100 pos nd trisom12 B 155
CLL-10 M 60 UM 100 pos neg del13q A 119
CLL-13 M 79 UM 98 pos pos 0 A 14
CLL-14 F 70 UM 100 pos neg trisom12 A 18
CLL-19 F 58 UM 100 pos neg 0 A 28
CLL-22 M 71 UM 99 pos pos del13q A 7
CLL-23 M 61 UM 100 pos pos 0 A 56
CLL-24 M 67 UM 99 pos nd trisom12 A 22
CLL-25 M 41 UM 99 pos pos del13q, del11q B 44
CLL-26 F 66 UM 100 pos neg del13q A 142
CLL-32 M 59 UM 100 pos pos trisom12 A 80
CLL-33 M 54 UM 100 pos neg del13q A 93
CLL-36 F 55 UM 99 pos neg del13q A 15
CLL-40 M 54 UM 100 pos pos del13q A 66
CLL-41 F 34 UM 99 pos neg 0 A 5
Continued
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with relevant guidelines and regulations. CLL cells were negatively selected from fresh blood samples using the 
RosetteSepTM B cell enrichment cocktail (StemCell Technologies, Grenoble, France) and density gradient cen-
trifugation (Ficoll®Paque Plus, GE Healthcare Life sciences, Velizy-Villacoublay, France). IGHV gene mutation 
status and ZAP70 expression were evaluated for each patient following established protocols48,49. Cytogenetic 
abnormalities were identified by metaphase analysis and fluorescence in situ hybridization (FISH) using a panel 
of probes as previously reported50. Total (CD19+) or naïve (CD19+, CD27+, IgM+) B cells were isolated from 
peripheral blood mononuclear cells (PBMC) of healthy blood donors using a negative selection kit (Human 
naïve B cell isolation kit, Human B cell isolation kit, StemcellTM Technologies, Grenoble, France) after density 
gradient centrifugation (Ficoll®Paque Plus, GE Healthcare Life sciences, Velizy-Villacoublay, France). The cell 
purity was then controlled by flow cytometry on a Cytomics FC500 System (Beckman-Coulter, Fullerton, CA) 
Figure 2. Cell proliferation of CLL and healthy B cells after soluble [anti-IgM + CD40L + IL-4 + IL-21] 
stimulation. (A) CLL cells isolated from a cohort of 59 CLL patients and healthy donors (naïve B cells, n = 16 or 
total B cells, n = 20) were stimulated ex vivo with anti-IgM, CD40L, IL-4 and IL-21. After initial CFSE staining 
(day 0), the percentage of cell proliferation was measured at day 6 for CLL cells and at day 4 for healthy B cells in 
stimulated cells (S) and control unstimulated cells (US). A threshold of dividing cells greater than 25% among 
living cells (dashed line) and the presence of at least one generation of daughter cells defines proliferation. 95% 
confidence interval for median is shown in each group. *p < 0.05; **p < 0.01; ***p < 0.001. Symbols represent 
CLL cells sub-types (circle: UM ZAP+; triangle: M ZAP+; square: M ZAP−; diamond: UM ZAP−). (B) For 
CLL cells responding to the stimulation, the number of cell generations, based on CFSE analysis, was quantified.
Sample Sex
Age at 
diagnosis
IGHV 
status*
VH identity 
(%)
ZAP70 
status**
CD38 
*** cytogenetic
Binet 
stage
Lymphocytes 
(G/L)
CLL-42 F 72 UM 100 pos pos del13q A 11
CLL-44 F 47 UM 99 pos neg 0 B 79
CLL-48 M 81 UM 100 pos neg del17p A 10
CLL-51 F 79 UM 100 pos neg del13q A 48
CLL-53 F 56 UM 100 pos neg del13q A 145
CLL-54 M 60 UM 99 pos neg nd A 15
CLL-55 M 72 UM 100 pos neg Trisom12, t(14;19) A 10
CLL-57 F 62 UM 99 pos neg 0 A 5
CLL-58 M 77 UM 100 pos neg 0 A 9
CLL-65 M 60 UM 100 pos neg 0 A 101
Table 1. Clinical and biological characteristics of CLL patients. *≥98% of VH identity for defining unmutated 
(UM) CLL B cells52. **<7 threshold of T-cells/CLL B cells ratio of ZAP70 mean fluorescence intensity 
expression for defining ZAP70 positive CLL cells49. ***≥30% threshold for defining CD38 positive CLL. nd 
indicates non determined.
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using CD19+ or CD19+/CD27− staining (Beckman Coulter, Villepinte, France). CLL B cell purity was assessed 
after CD19+/CD5+ staining (Beckman Coulter, Villepinte, France) and ranged from 90% to 99% (median 97%). 
Cell differentiation was studied after anti-CD38 and anti-CD138 stainings (Beckman Coulter, Villepinte, France) 
at days 0 and 6.
Culture conditions. Cells were cultured in RPMI 1640 Medium (Gibco, Paisley, UK) supplemented with 
10% fetal calf serum (FCS) (Dutscher, Brumath, France) and 1% penicillin/streptomycin (Gibco, New York, 
USA), with or without methylcellulose (MethoCultTM, StemcellTM Technologies, Vancouver, Canada) at 37 °C, 
in an atmosphere enriched with 5% CO2. B cells at a density of 106 cells/ml were stimulated in the absence or pres-
ence of 10 µg/ml of soluble F(ab’)2 anti-human IgM (Jackson ImmunoResearch, West Grove, PA, USA), 100 ng/
ml of trimeric CD40L (Enzo Life Science, Villeurbanne, France), 10 ng/ml of IL-4 (R&D Systems-Bio-Techne, 
Lille, France) and 25 ng/ml of IL-21 (Invitrogen, Maryland, USA). Il-21 was added 24 h after initial stimulation 
with anti-IgM, CD40L and IL-4 by up/down pipetting in soluble and methyl cellulose medium. In each well, 
100 µl of fresh soluble medium was added at Day 3. Other culture conditions included CpG (ODN2006, 5 µg/ml, 
InvivoGen, San Diego, USA), IL-15 (15 ng/ml, R&D), IL-2 (10 ng/ml, R&D) and PremixAmpliB DSP30/IL-2 (50 
or 100 µg/106 cells) (Amplitech, Compiegne, France). After 6 days, proliferation was assessed by flow cytometry.
Control and CLL cells were co-cultured on fibroblasts (3T6 cells) stably transfected with either a plasmid 
encoding human CD40L (3T6-CD40L) or mock transfected (3T6). Fibroblasts were pre-cultured overnight in 
48-well plates (Dutscher, Brumath, France) at 5.104 cells/well. At day 1, fibroblasts were X-ray-irradiated (30 Gy) 
and re-cultured overnight. At day 2, carboxyfluorescein succinimidyl ester (CFSE) labeled B cells (106 cells/ml) 
were added to the fibroblast layer (10 CLL cells/1 fibroblast). At day 6 and after CD19 staining, B cells prolifera-
tion was evaluated by flow cytometry.
Figure 3. Cell proliferation of CLL and healthy B cells after [anti-IgM + CD40L + IL-4 + IL-21] stimulation 
on a semi-solid medium. (A) CLL cells isolated from a cohort of 38 CLL patients and naïve and total B cells 
(n = 11) isolated from healthy donors have been stimulated ex vivo with anti-IgM, CD40L, IL-4 and IL-21 
on a semi-solid culture medium. After initial CFSE staining (day 0), the percentage of cell proliferation was 
measured at day 6 for CLL cells and at day 4 for healthy B cells in stimulated cells (S) and control unstimulated 
cells (US). *p < 0.05; **p < 0.01; ***p < 0.001. Symbols represent CLL cells sub-types (circle: UM ZAP+; 
triangle: M ZAP+; square: M ZAP−; diamond: UM ZAP−). (B) Comparison of CLL cells proliferation 
after anti-IgM, CD40L, IL-4 and IL-21 stimulation in soluble and semi-solid medium. (C) Number of cell 
generations for responding CLL cells stimulated in soluble and semi-solid medium.
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CFSE-based proliferation assays. Freshly isolated B cells were labeled with 0.5 μM CellTraceTM CFSE 
(ThermoFisher, Waltham, MA, USA) and incubated for 10 min at 37 °C in the dark. Washed CFSE-labeled cells 
were stimulated and cultured at 37 °C/5% CO2. Four or six days later, B cell proliferation was evidenced by a cell 
division-dependent decrease in CFSE staining intensity as evaluated by flow cytometry (Fig. S1). Fluorescence 
data were analyzed with CXP (Beckman Coulter, Fullerton, CA) and FlowJo v.8.7 (TreeStar, Ashland, USA) 
softwares.
Apoptosis assay. Cell apoptosis was evaluated using FITC annexin-V Apoptosis detection kit and propid-
ium iodide (PI) (both from BD Pharmingen, BD Bioscience, San Jose, CA, USA). Cells (106) were washed in 
phosphate-buffered saline (PBS) and re-suspended in annexin buffer before the addition of FITC annexin-V 
Figure 4. Additive effect of TLR9 activation on CLL cells after [anti-IgM + CD40L + IL-4 + IL-21] 
stimulation. (A) CLL cells (n = 39) were stimulated either by CpG-ODN2006, or IgM + CD40L + IL-4 + IL-21 
or the combination of CpG-ODN2006 and anti-IgM + CD40L + IL-4 + IL-21. After initial CFSE staining 
(day 0), the percentage of cell proliferation was measured at day 6 in soluble medium and (B) in semi-
solid medium. (C) Determination of the number of cell generations for responding CLL cells after anti-
IgM + CD40L + IL-4 + IL-21 stimulation with or without CpG-ODN2006 in soluble medium and (D) in semi-
solid medium. (E) Comparison of CLL cells proliferation after anti-IgM + CD40L + IL-4 + IL-21 stimulation 
with or without CpG-ODN2006 in soluble medium and (F) in semi-solid medium. Symbols represent CLL 
cells sub-types (circle: UM ZAP+; triangle: M ZAP+; square: M ZAP−; diamond: UM ZAP−). *p < 0.05; 
**p < 0.01; ***p < 0.001.
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and incubated for 20 min on ice in the dark. PI was then added for 5 min before flow cytometry analysis. DAPI 
(Sigma-Aldrich; Missouri, USA) was also used to analyze cell viability.
Western blotting. After stimulation, B cells were centrifuged and cell pellets re-suspended in lysis buffer 
(1% Triton X-100, 20 mM Tris-HCl [pH 8], 130 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM PMSF, and pro-
tease inhibitors) for 20 minutes on ice. Lysates were centrifuged for 10 minutes at 300 g at 4 °C, and supernatants 
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred electro-
phoretically to polyvinylidene difluoride (PVDF) membranes. Membranes were then blocked using 5% milk 
in Tris-buffered saline (TBS; 20 mM Tris [pH 7.5], 150 mM NaCl) for 1 h at room temperature. The blots were 
then incubated with anti-ZAP70 (Clone E267) (Abcam, Paris, France), anti-phospho ZAP70Tyr319 (Abcam, Paris, 
Figure 5. Proliferative response according to the IGHV mutational status and ZAP70 protein expression. 
Recapitulation of CLL cells proliferation for UM ZAP+ (circle), M ZAP70+ (triangle) and M ZAP70− (square) 
CLL cells after anti-IgM + CD40L + IL-4 + IL-21 stimulation in soluble medium, semi-solid medium, soluble 
medium + CpG-ODN2006 and semi-solid medium + CpG-ODN2006. *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 6. Signaling pathways activated by [anti-IgM + CD40L + IL-4 + IL-21] stimulation of responding and 
non-responding UM ZAP70+ CLL cells. (A) Normalized protein expression of ZAP70, phospho-ZAP70Tyr319/
SYKTyr352 (pZAP70/pSYK), phospho-SYKTyr323 (pSYK), phospho-AKTThr308 (pAKT), phospho-ERK1/2Tyr204 
(pERK), phospho-IκBSer32/36 (pIκB) and phospho-STAT6Tyr641 (pSTAT6), based on immunoblot results of 
proliferating (Responders, n = 4) and non-proliferating (Non Responders, n = 3) UM-CLL ZAP+ CLL cells 
following stimulation (S) or in unstimulated (US) conditions. Protein expression corresponds to the value of a 
signal (determined with ImageJ) normalized to that of GAPDH. (B) Role of IL-4 co-stimulation on CLL cells 
proliferation. CLL cells isolated from 6 CLL patients were stimulated ex vivo with anti-IgM, CD40L, IL-4 and 
IL-21, with or without a specific JAK3 inhibitor (PF-956980), or with anti-IgM, CD40L and IL-21. After initial 
CFSE staining (at day 0), the percentage of cell proliferation was measured at day 6. Symbols (circle) represent 
UM ZAP+ CLL cells. 95% confidence interval for median is shown in each graph. *p < 0.05; **p < 0.01; 
***p < 0.001.
www.nature.com/scientificreports/
1 0ScIentIfIc REpoRTS |           (2019) 9:701  | DOI:10.1038/s41598-018-36853-8
France) - which recognizes also SYKTyr352 phosphorylation in CLL B cells46 -, anti-phospho-SYKTyr323 (Santa Cruz, 
Nanterre, France), anti-phospho-ERK1/2Tyr204 (clone E-4) (Santa Cruz, Nanterre, France), for 2 h at room temper-
ature, anti-phospho-STAT6Tyr641 (Cell Signaling, France), anti-phospho-AKTThr308 (clone D25E6) (Cell Signaling), 
anti-phospho-IkBSer32/36 (clone 5A5) (Cell Signaling), anti-phospho-STAT3Tyr705 (clone EP2147Y) (GeneTex), 
anti-STAT3 (clone 79D7) (Cell Signaling) overnight at 4 °C, followed by incubation with horseradish peroxi-
dase (HRP)-conjugated goat anti-mouse IgG or anti-rabbit monoclonal antibodies (1 h at 25 °C), and revealed by 
Electro Chemo Luminescence (ECL Plus Western blotting Detection Reagents (Amersham, Courtaboeuf, France) 
or SuperSignal West Femto Maximum Sensitivity substrate (Pierce, Courtaboeuf, France), according to manu-
facturers’ instructions. To confirm the presence of equal amounts of loaded proteins, membranes were incubated 
with anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, clone 6C5) (Merck Millipore, Guyancourt, 
France). Signals were visualized by chemiluminescence and processed by the Image LabTM software (BioRad, 
Marnes-la Coquette, France). The relative intensity of bands was measured and calculated using the Image J 
software (http://rsb.info.nih.gov/ij/index.html). The abundance of each protein has been normalized to GAPDH 
within the same sample on the same western blot.
Statistical analyses. Statistical analyses were performed using R 3.2.4 (R Core Team, 2016, R Foundation 
for Statistical Computing, Vienna, Austria). Graphics were created using Graphpad Prism 7.0 (Graphpad 
Software; Inc, La Jolla, CA, USA). We used permutational ANOVA for repeated measurements (lmPerm R pack-
age, https://github.com/mtorchiano/lmPerm) to compare more than two groups. Posthoc tests were done using 
nonparametric multiple comparisons tests carried out with the nparcomp R package51. Differences between two 
groups were assessed using either nonparametric Wilcoxon matched-pairs signed rank test of nonparametric 
Mann-Whitney test (unpaired, when applicable). A p value of <0.05 was considered statistically significant. 
*p < 0.05; **p < 0.01; ***p < 0.001.
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